On April 5, 2017, Claude Ranoux submitted his letter of resignation effective immediately as a member of the Board of Directors to INVO Bioscience, Inc.’s Board of Director’s Chairperson and CEO Kathleen Karloff. Due to disagreements on how to run the business, Claude Ranoux had initially indicated that he wanted Kathleen Karloff be replaced as an officer. Instead, as previously reported by the Corporation, on September 20, 2016 the Board of Directors replaced Claude Ranoux as President and Treasurer, and removed Claude Ranoux as Chief Scientist, of the Corporation, with Kathleen Karloff then being elected Chairman of the Board, President and CEO, and Robert Bowdring being elected Treasurer and Secretary of the Corporation. Claude Ranoux voted against those changes. Since those changes Dr. Ranoux has voted against virtually all of the actions taken by the Board of Directors, which actions were approved by Ms. Karloff and Mr. Bowdring. Due to these disagreements, Dr. Ranoux has indicated his desire to replace Ms. Karloff and Mr. Bowdring as directors as well as change the Corporation’s management. The Board of Directors believes Dr. Ranoux’s resignation was caused by Dr. Ranoux ceasing to be the President, Treasurer and Chief Scientist of the Corporation, the election of Ms. Karloff and Mr. Bowdring to their new officer positions.